| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/15/2011 | CA2460340C Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors |
| 02/15/2011 | CA2458856C Improved therapeutic protocols |
| 02/15/2011 | CA2455453C Taxol enhancer compounds |
| 02/15/2011 | CA2452502C 2-(3,5-bis-trifluoromethyl-phenyl)-n-[6-(1,1-dioxo-1.lambda.6-thiomorpholin-4-yl)-4-(2-methyl or 4-fluoro-2-methyl substituted)phenyl-pyridin-3-yl]-n-methyl-isobutyramide |
| 02/15/2011 | CA2452445C Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof |
| 02/15/2011 | CA2446864C Inhibitors of src and other protein kinases |
| 02/15/2011 | CA2433071C Use of transcription factor yb-1 in adenoviral systems |
| 02/15/2011 | CA2416757C Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same |
| 02/15/2011 | CA2408332C Supports for photosensitizer formulations |
| 02/15/2011 | CA2407046C Immunoregulator |
| 02/15/2011 | CA2406930C Preparation of aqueous clear solution dosage forms with bile acids |
| 02/15/2011 | CA2383424C Novel b7-4 molecules and uses therefor |
| 02/15/2011 | CA2377085C Substituted benzimidazoles |
| 02/15/2011 | CA2373554C Process for the preparation and purification of thiol-containing maytansinoids |
| 02/15/2011 | CA2354046C New cancer treatments |
| 02/15/2011 | CA2294223C Anti-cd40l immunotoxins for the treatment of diseases |
| 02/15/2011 | CA2286397C Humanized antibodies and methods for forming humanized antibodies |
| 02/15/2011 | CA2192235C Flt4 receptor tyrosine kinase and its use in diagnosis and therapy |
| 02/15/2011 | CA2189691C Novel tetrapeptides, their preparation and use |
| 02/11/2011 | CA2807557A1 Diagnosis of primary and metastatic basal-like breast cancer and other cancer types |
| 02/10/2011 | WO2011017639A1 Methods of using c-met modulators |
| 02/10/2011 | WO2011017534A2 Treatment of prostate cancer |
| 02/10/2011 | WO2011017519A2 Inhibitors of methionine aminopeptidases and methods of treating disorders |
| 02/10/2011 | WO2011017456A2 Localized delivery of nanoparticles for therapeutic and diagnostic applications |
| 02/10/2011 | WO2011017350A2 Compounds as lysophosphatidic acid receptor antagonists |
| 02/10/2011 | WO2011017162A2 Methods for enhancing antigen-specific immune responses |
| 02/10/2011 | WO2011017143A2 Compositions and methods of preparing alloreactive cytotoxic t cells |
| 02/10/2011 | WO2011017142A1 Novel bicyclic urea compounds |
| 02/10/2011 | WO2011017107A2 Microbubble assisted viral delivery |
| 02/10/2011 | WO2011017096A2 Methods of treating hematologic cancers |
| 02/10/2011 | WO2011017009A1 Novel azaheterocyclic compounds |
| 02/10/2011 | WO2011016674A2 Novel organic germanium compounds |
| 02/10/2011 | WO2011016576A1 Alanine derivatives as inhibitors of apoptosis proteins |
| 02/10/2011 | WO2011016561A1 Dna capable of inducing osteoblast-specific expression, and nucleotide sequence for same |
| 02/10/2011 | WO2011016528A1 Aminopyrazole derivative |
| 02/10/2011 | WO2011016501A1 Prophylactic or therapeutic agent for cancer |
| 02/10/2011 | WO2011016472A1 Pyridine and pyrimidine derivatives having ttk-inhibiting activity |
| 02/10/2011 | WO2011016461A1 Tumor angiogenesis inhibitor |
| 02/10/2011 | WO2011016459A1 Thienooxazepine derivative |
| 02/10/2011 | WO2011016432A1 Immune balance-regulating agent |
| 02/10/2011 | WO2011016351A1 Dna synthase inhibitors |
| 02/10/2011 | WO2011015728A1 Novel dihydroindolone derivatives, process for the preparation thereof and pharmaceutical compositions containing same |
| 02/10/2011 | WO2011015652A1 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives as c-met tyrosine kinase modulators |
| 02/10/2011 | WO2011015040A1 Methods and compositions for the diagnosis and prognosis of cervical intraepithelial neoplasia and cervical cancer |
| 02/10/2011 | WO2011014925A1 Process for obtaining peptide fractions |
| 02/10/2011 | WO2010068810A3 Certain substituted amides, method of making, and method of use thereof |
| 02/10/2011 | WO2010003992A8 Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer |
| 02/10/2011 | US20110035817 Siva 3, its preparation and use |
| 02/10/2011 | US20110034916 Nanoparticle-mediated microwave treatment methods |
| 02/10/2011 | US20110034568 Compositions comprising lecithin oils and NSAIDS for protecting the gastrointestinal tract and providing enhanced therapeutic activity |
| 02/10/2011 | US20110034564 Soluble complexes of curcumin |
| 02/10/2011 | US20110034550 Inclusion Compounds of Fumagillol Derivative or its Salt, and Pharmaceutical Compositions Comprising the Same |
| 02/10/2011 | US20110034549 Antitumoral Compounds |
| 02/10/2011 | US20110034547 Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof |
| 02/10/2011 | US20110034545 Double-stranded lipid-modified rna having high rna interference effect |
| 02/10/2011 | US20110034542 Novel synthetic analogs of sphingolipids |
| 02/10/2011 | US20110034538 MicroRNA-Based Methods and Compositions for the Diagnosis, Prognosis and Treatment of Gastric Cancer |
| 02/10/2011 | US20110034536 Controlling the potential of primate neural stem cells by regulating pax6 |
| 02/10/2011 | US20110034532 Modulation of T Cell Signaling Threshold and T Cell Sensitivity to Antigens |
| 02/10/2011 | US20110034531 Use of hdac inhibitors for the treatment of melanoma |
| 02/10/2011 | US20110034529 Benzene, pyridine, and pyridazine derivatives |
| 02/10/2011 | US20110034527 Novel 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
| 02/10/2011 | US20110034524 Hemi-fumarate salt of a 1,3,4-thiadiazolyl derivative as modulator of the sphingosine 1-phosphate receptor |
| 02/10/2011 | US20110034521 Compounds and methods for treating zinc matrix metalloprotease dependent diseases |
| 02/10/2011 | US20110034507 Farnesoid x receptor agonists |
| 02/10/2011 | US20110034505 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
| 02/10/2011 | US20110034503 Rapamycin and its derivatives for the treatment of liver-associated fibrosing disorders |
| 02/10/2011 | US20110034498 Dosing regimens for the treatment of cancer |
| 02/10/2011 | US20110034497 Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
| 02/10/2011 | US20110034487 Cxcr3 antagonists |
| 02/10/2011 | US20110034485 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture |
| 02/10/2011 | US20110034477 Crystalline Polymorph of Doxazosin Mesylate (Form IV) and Process for Preparation Thereof |
| 02/10/2011 | US20110034474 Pyridazinone derivatives |
| 02/10/2011 | US20110034473 Novel (pyrroloquinoxalinyl) pyrazinecarbohydrazide-oxalic acid co-crystal for treatment of cancer and other diseases |
| 02/10/2011 | US20110034472 Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function |
| 02/10/2011 | US20110034470 Inhibitors of JNK |
| 02/10/2011 | US20110034469 Heterocyclic Compound |
| 02/10/2011 | US20110034462 Organic compounds |
| 02/10/2011 | US20110034461 Sf5 derivatives as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034460 Dihydroindolone compounds, a process for their preparation and pharmaceutical compositions containing them |
| 02/10/2011 | US20110034459 6,7-dialkoxy quinazoline derivatives and methods of treating drug resistant and other tumors |
| 02/10/2011 | US20110034458 Pyridine methylene azolidinones and use thereof phosphoinositide inhibitors |
| 02/10/2011 | US20110034457 Pyridothiophene Compounds |
| 02/10/2011 | US20110034456 Imidazopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034454 Morpholino pyrimidine derivatives and their use in therapy |
| 02/10/2011 | US20110034452 Triazolium salts as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034451 Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments |
| 02/10/2011 | US20110034441 Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof |
| 02/10/2011 | US20110034439 Acylthiourea compound or salt thereof, and use thereof |
| 02/10/2011 | US20110034438 Structural mimetics of proline-rich peptides and the pharmaceutical use thereof |
| 02/10/2011 | US20110034436 spirocyclic aminoquinolnes as gsk-3 inhibitors |
| 02/10/2011 | US20110034431 Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer |
| 02/10/2011 | US20110034428 Treatment of Prostate Cancer |
| 02/10/2011 | US20110034425 Method of Treatment for Acute Myelogenous Leukemia |
| 02/10/2011 | US20110034416 4-pyridinone compounds and their use for cancer |
| 02/10/2011 | US20110034413 Novel quercetin derivatives as anti-cancer agents |
| 02/10/2011 | US20110034399 Liquid and Freeze Dried Formulations |
| 02/10/2011 | US20110034398 Use of imp3 as a prognostic marker for cancer |
| 02/10/2011 | US20110034397 Intestinal immune system stimulator |
| 02/10/2011 | US20110034386 Dendroaspis natriuretic peptide for treatment of cancer |